Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News

Stay up to date with the exciting new developments as we continue to grow.

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Filter by date

30 Apr 2019

2018 Annual Report and 2019 AGM Notice

Shield Therapeutics plc, announces that the following documents have been sent to shareholders: ·     Annual Report and Accounts for the year ended 31 December 2018…

24 Apr 2019

Feraccru® granted major extension to approval in Switzerland

Shield Therapeutics plc, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now…

3 Apr 2019

Preliminary Results for the Year Ended 31 December 2018

Shield Therapeutics plc, announces its preliminary Group results for the year ended 31 December 2018. For full details click here.

1 Apr 2019

Shield Therapeutics plc – change of Adviser

Shield Therapeutics plc, announces the appointment of Peel Hunt LLP as its Nominated Adviser with immediate effect. Peel Hunt will continue to act as broker…

27 Mar 2019

Notice of results – Analyst and investor briefings

Shield Therapeutics plc, will be announcing its final results for the financial year ended 31 December 2018 on Wednesday 3 April 2019. Analyst briefing A…

14 Mar 2019

European Patent Office reaches positive decision on Feraccru®’s process patent

  Shield Therapeutics plc, announces that, further to the announcement on 24 January 2019 and in relation to the Group’s patent #2 668 175, which…

29 Jan 2019

Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru®

Shield Therapeutics plc, announces positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru®, a novel oral ferric iron therapy that…

24 Jan 2019

Shield Therapeutics plc, business and trading update

Shield Therapeutics plc,  today provides a business and unaudited trading update for the year ended 31 December 2018. For further details and to view the…

23 Jan 2019

Investor presentations

Shield Therapeutics plc, announces it will be presenting at two investor presentations this month. For further details please click here or visit our events page.  …